Karyopharm Therapeutics (NASDAQ:KPTI) Given New $25.00 Price Target at Robert W. Baird

Karyopharm Therapeutics (NASDAQ:KPTI) had its price objective cut by Robert W. Baird from $42.00 to $25.00 in a research note published on Tuesday morning,Benzinga reports. They currently have an outperform rating on the stock.

A number of other equities analysts have also recently issued reports on the company. Barclays upped their price objective on Karyopharm Therapeutics from $5.00 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, May 13th. Wall Street Zen cut Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 14th. HC Wainwright cut Karyopharm Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, July 16th. Finally, Royal Bank Of Canada dropped their target price on Karyopharm Therapeutics from $34.00 to $33.00 and set an “outperform” rating for the company in a report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Karyopharm Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.00.

Karyopharm Therapeutics Price Performance

Shares of KPTI opened at $4.02 on Tuesday. The firm has a market cap of $34.73 million, a PE ratio of -0.28 and a beta of 0.28. The stock’s fifty day moving average price is $4.31 and its two-hundred day moving average price is $5.69. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $16.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Monday, August 11th. The company reported ($4.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.80) by ($0.52). The company had revenue of $37.93 million during the quarter, compared to the consensus estimate of $37.92 million. Sell-side analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. boosted its stake in shares of Karyopharm Therapeutics by 46.3% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company’s stock worth $4,274,000 after buying an additional 2,000,000 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Karyopharm Therapeutics by 15.3% in the 4th quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock worth $1,633,000 after buying an additional 319,187 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Karyopharm Therapeutics by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock worth $942,000 after buying an additional 36,922 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Karyopharm Therapeutics by 265.5% in the 4th quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock worth $506,000 after buying an additional 543,556 shares during the last quarter. Finally, Silverarc Capital Management LLC boosted its stake in shares of Karyopharm Therapeutics by 6.7% in the 4th quarter. Silverarc Capital Management LLC now owns 595,990 shares of the company’s stock worth $403,000 after buying an additional 37,524 shares during the last quarter. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).